TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01189097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
Study: NCT03176771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5199
Description: MT-5199 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5199
Description: MT-5199 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5199
Description: MT-5199 40 mg capsules
Study: NCT01099215

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PVS-10200
Description: PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
Study: NCT04079751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Mechanical Alignment
Description: Hip-knee-ankle angle of 180° ± 3°.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Alignment
Description: Restoring a patient's pre-diseased limb alignment
Study: NCT02816775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
Study: NCT03176771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5199
Description: MT-5199 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules
Study: NCT02484677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxanes. Blood sampling for pharmacokinetic evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracile
Description: Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
Study: NCT03927443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-133
Description: one drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan
Description: one drop
Study: NCT00106002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
Study: NCT02059707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT RS Suture Delivery Device
Description: LARIAT RS Suture Delivery Device
Study: NCT02517281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT04246463

Intervention type: DEVICE
Intervention: Thoracic
Description: Implant of a Relay stent graft system

Intervention type: DEVICE
Intervention: Abdominal
Description: Implant with an Anaconda or Treo Stent graft system

Intervention type: DEVICE
Intervention: Custom Device
Description: Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device

Intervention type: DEVICE
Intervention: Illiac Artery
Description: Implant with an Anaconda Iliac leg only
Study: NCT04382534

Intervention type: COMBINATION_PRODUCT
Intervention: Respiratory rehabilitation
Description: Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
Study: NCT02816775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGRATH Videolaryngoscope
Description: After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
Study: NCT02309931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antiperistaltic side-to-side ileocecal anastomosis
Description: Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isoperistaltic side-to-side ileocecal anastomosis
Description: Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
Study: NCT02822105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the H3N2 M2SR monovalent influenza vaccine
Description: The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline
Study: NCT01544036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren
Description: Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
Study: NCT00667511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NxStage System One
Description: Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NxStage System One
Description: Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
Study: NCT02426697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl transmucosal
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Study: NCT04456686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: LY3016859 given IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV.
Study: NCT03409965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic Infini System
Description: A microneedle radiofrequency device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic LaseMD System
Description: A fractional thulium laser device
Study: NCT03670992

Intervention type: PROCEDURE
Intervention: duodenal-pancreatectomy
Description: surgical removal of metastatic repetitions in pancreas and/or other distal sites

Intervention type: PROCEDURE
Intervention: duodenal-pancreatectomy
Description: surgical removal of metastatic repetitions in pancreas and/or other distal sites
Study: NCT03857256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP105F
Description: Natural Health Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP105F
Description: Natural Health Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP105F
Description: Natural Health Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet manufactured to mimic the CP105F beta-glucan
Study: NCT01201863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel (Testosterone Gel)
Description: 2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
Study: NCT04103840

Intervention type: OTHER
Intervention: Testing stool mycobiota
Description: Both cohorts of SAH and their family controls will be tested for fecal mycobiota

Intervention type: OTHER
Intervention: Testing stool mycobiota
Description: Both cohorts of SAH and their family controls will be tested for fecal mycobiota
Study: NCT04207671

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Complete omission of chest tube
Description: No chest tube implacement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Improved drainage strategy
Description: A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
Study: NCT04337632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection+carboplatin
Description: Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel +carboplatin
Description: paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
Study: NCT03980119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITSystem 3.0
Description: The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
Study: NCT03118050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Supervised resistance exercise training, 3 times a week for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days
Study: NCT01464372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Field Stimulation Device
Description: Treatment with Electrical Field Stimulation Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nerve Stimulation Device
Description: Use of the sham device
Study: NCT01788462

Intervention type: DRUG
Intervention: Tesamorelin (Egrifta)
Description: We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
Study: NCT02070939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
Study: NCT03118050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Description: Intensive weight bearing PT, daily, during bed rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Description: Intensive weight bearing PT, daily, during bed rest
Study: NCT02915835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
Study: NCT02070939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
Study: NCT01802151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. subtilis R0179
Description: B. subtilis R0179 for a period of 4 weeks. One capsule per day.
Study: NCT02123641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy resistance training
Description: Supervised heavy resistance training three times weekly for 52 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Description: Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No training
Study: NCT02426801

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
Study: NCT03426345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily for 12 weeks.
Study: NCT01149941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study: NCT03534024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nanomicielle curcumin
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study: NCT03265561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone allograft
Description: All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone auto and allograft group
Description: All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
Study: NCT01448733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Description: Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
Study: NCT02865161

Intervention type: DRUG
Intervention: NISELAT
Description: NISELAT 600MG BD
Study: NCT03277131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DURAFIBER Ag
Description: DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
Study: NCT01802151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. subtilis R0179
Description: B. subtilis R0179 for a period of 4 weeks. One capsule per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. subtilis R0179
Description: B. subtilis R0179 for a period of 4 weeks. One capsule per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
Study: NCT04559321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.
Description: General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.
Description: General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
Study: NCT00107887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH preventive therapy
Description: Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
Study: NCT00244439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG
Description: 30 minute application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovide (malathion) lotion 0.05%
Description: 8-12 hour application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1%
Description: 10 minute application